

Frederik Nevens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8572330/publications.pdf>

Version: 2024-02-01

62
papers

4,725
citations

186265

28
h-index

128289

60
g-index

62
all docs

62
docs citations

62
times ranked

5131
citing authors

#	ARTICLE	IF	CITATIONS
1	Telemedicine based remote monitoring after liver transplantation: Feasible in a select group and a more stringent control of immunosuppression. <i>Clinical Transplantation</i> , 2022, 36, e14494.	1.6	7
2	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1545-1553.	3.7	33
3	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	4.4	30
4	Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate. <i>Hepatology</i> , 2021, 73, 2598-2600.	7.3	11
5	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1514-1522.	0.4	14
6	Is there a role for neuregulin 4 in human nonalcoholic fatty liver disease?. <i>PLoS ONE</i> , 2021, 16, e0251822.	2.5	4
7	Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study. <i>Transplantation Direct</i> , 2021, 7, e722.	1.6	1
8	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1138-1146.	3.7	37
9	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	4.4	17
10	Renal disease in the allograft recipient. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101690.	2.4	9
11	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.4	74
12	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	3.7	47
13	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020, 69, 1502-1509.	12.1	28
14	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	1.6	2
15	Further Evidence That Lanreotide Reduces Liver Growth in Patients With Polycystic Liver Disease, But Not the End of the Story. <i>Gastroenterology</i> , 2019, 157, 298-299.	1.3	0
16	Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion. <i>Viruses</i> , 2019, 11, 687.	3.3	7
17	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	4.4	54
18	Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBsAg seroconversion. <i>Journal of Viral Hepatitis</i> , 2019, 26, 766-769.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Prevalence and risk factors of hepatitis B virus infection in Middle Limburg Belgium, year 2017: Importance of migration. <i>Journal of Medical Virology</i> , 2019, 91, 1479-1488.	5.0	9
20	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	3.7	148
21	YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role. <i>International Journal of Molecular Sciences</i> , 2019, 20, 638.	4.1	44
22	High-throughput sequencing identifies aetiology-dependent differences in ductular reaction in human chronic liver disease. <i>Journal of Pathology</i> , 2019, 248, 66-76.	4.5	37
23	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1792-1800.e3.	4.4	127
24	Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction. <i>Gastroenterology</i> , 2018, 154, 1361-1368.	1.3	13
25	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.4	64
26	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	7.3	55
27	Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1713-1716.	0.5	7
28	How to Deal With a Nonextractable Transjugular Intrahepatic Portosystemic Shunt Complicating Liver Transplantation. <i>Liver Transplantation</i> , 2018, 24, 1293-1297.	2.4	1
29	Variable efficacy of TIPSS in the management of ectopic variceal bleeding: a multicentre retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 975-983.	3.7	24
30	Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. <i>Lipids in Health and Disease</i> , 2017, 16, 46.	3.0	19
31	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, S1-S56.	1.0	217
32	Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. <i>Infection, Genetics and Evolution</i> , 2017, 53, 15-23.	2.3	14
33	Belgian experience with direct acting antivirals in people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2017, 177, 214-220.	3.2	31
34	Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. <i>Hepatology</i> , 2017, 66, 1232-1241.	7.3	72
35	Expanded polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunts in cirrhotic patients: Long-term patency and clinical outcome results. <i>European Radiology</i> , 2017, 27, 1795-1803.	4.5	26
36	De novo Malignancy and Recurrent Alcoholic Cirrhosis Account for 70% of Deaths in Patients Transplanted for End-Stage Alcoholic Liver Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 436-437.	0.4	5

#	ARTICLE	IF	CITATIONS
37	A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2016, 9, 139-146.	3.7	7
38	Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. <i>Journal of Hepatology</i> , 2016, 64, 609-617.	3.7	102
39	Global genotype distribution of hepatitis C viral infection among people who inject drugs. <i>Journal of Hepatology</i> , 2016, 65, 1094-1103.	3.7	63
40	Acute-on-chronic liver failure in cirrhosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16041.	30.5	320
41	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	12.1	139
42	CD14+ macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharide. <i>BMC Infectious Diseases</i> , 2015, 15, 430.	2.9	16
43	Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus. <i>Transplantation</i> , 2015, 99, 1455-1462.	1.0	109
44	Reply to: "Development and validation of a polycystic liver disease complaint-specific assessment (POLCA) – Use of the Delphi technique for content validation". <i>Journal of Hepatology</i> , 2015, 62, 989.	3.7	1
45	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	1.3	330
46	Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2353-2359.e1.	4.4	29
47	Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis. <i>Gut</i> , 2015, 64, 673-683.	12.1	64
48	The Impact of Liver Transplantation after Surgical Treatment of Hepatocellular Carcinoma. <i>Frontiers in Surgery</i> , 2014, 1, 29.	1.4	0
49	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	1.3	365
50	Development and validation of a polycystic liver disease complaint-specific assessment (POLCA). <i>Journal of Hepatology</i> , 2014, 61, 1143-1150.	3.7	27
51	A near-full length genotypic assay for HCV1b. <i>Journal of Virological Methods</i> , 2014, 209, 126-135.	2.1	11
52	Noncutaneous head and neck cancer in solid organ transplant patients: Single center experience. <i>Oral Oncology</i> , 2014, 50, 263-268.	1.5	10
53	Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1724-1730.e5.	4.4	41
54	Young Women With Polycystic Liver Disease Respond Best to Somatostatin Analogues: A Pooled Analysis of Individual Patient Data. <i>Gastroenterology</i> , 2013, 145, 357-365.e2.	1.3	76

#	ARTICLE	IF	CITATIONS
55	Resource use and cost of hepatitis C-related care. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1191-1198.	1.6	19
56	Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. <i>New England Journal of Medicine</i> , 2010, 362, 2370-2379.	27.0	1,075
57	Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial. <i>Liver Transplantation</i> , 2009, 15, 1262-1269.	2.4	137
58	Lanreotide Reduces the Volume of Polycystic Liver: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2009, 137, 1661-1668.e2.	1.3	233
59	Portal hypertension: from pathophysiology to clinical practice. <i>Liver International</i> , 2005, 25, 1079-1090.	3.9	108
60	The molecular adsorbent recycling system (MARS) and transmembrane transport of albumin-bound toxins. <i>Liver Transplantation</i> , 2005, 11, 853-854.	2.4	10
61	Aplastic anemia after transplantation for non-A, non-B, non-C fulminant hepatic failure: case report and review of the literature. <i>Transplant International</i> , 2002, 15, 117-123.	1.6	25
62	Liver transplantation for polycystic liver disease. <i>Liver Transplantation</i> , 2001, 7, 238-245.	2.4	113